ORIGINAL ARTICLE

The efficacy and safety of oral mucopolysaccharide, type I collagen and vitamin C treatment in tendinopathy patients

Andreu Arquer a, Miquel García b, José Antonio Laucirica c, Marta Rius d, Marian Blàvia e, Jaume Fontserè f, Carlos Hernández g, Jordi Boluda h, Tomislav Kranjcec i, Ana de la Torre j, Gilberto Díaz k, Karin Freitag l, José M. Villalón m, Jaime Baselga n, Pedro Hernández o, José Gonzalez p, Guillermo Rodríguez q, Horacio Rodríguez r, Juan María Alarcón s, Carlos T. Simorte t, Isaac Vicente u, Montserrat Cabanas v, Pablo Ramírez w, Daniel Martínez Puig x*

a Centre d’Alt Rendiment (CAR-GIRSANE), Sant Cugat, Barcelona, Spain
b Clínica Teknon, Barcelona, Spain
c Artro Esport, Barcelona, Spain
d Mútua Catalana de Fútbol, Barcelona, Spain
e Clínica Diagonal, Esplugues de Llobregat, Barcelona, Spain
f Traumasalut, Sabadell, Spain
g Xarxa Sanitaria i Social de Santa Tecla (Unitat de Medicina de l’Esport), Tarragona, Spain
h Lenox Corachan, Barcelona, Spain
i Activa Mútua, Clínica Diagonal y Centros, Barcelona, Spain
j Clínica CEMTRO, Madrid, Spain
k Clínica Asepeyo, Madrid, Spain
l Centro Integral del Aparato Locomotor, Madrid, Spain
m Hospital Universitario Montepríncipe, Madrid, Spain
n Hospital Ruber Internacional, Madrid, Spain
o Clínica DEYRE, Madrid, Spain
p Clínica Nuestra Señora Avda. América, Madrid, Spain
q Hospital de Madrid, Madrid, Spain
r BIOIBERICA S.A., Palafolls, Barcelona, Spain
s Hospital de Madrid, Madrid, Spain

Received 13 September 2013; accepted 3 December 2013

KEY WORDS
Tendinopathy;
Clinical trial;
Diet supplement

Abstract
Introduction and objectives: Tendinopathy, which is accompanied by structural changes to the tendon, is a common sporting injury. The aim of this study was to evaluate the efficacy and safety of a nutritional supplement containing mucopolysaccharides, type I collagen and vitamin C (Tendoactive™) on the clinical and structural evolution of
**Introduction**

Tendon damage arising due to overload or a tendinopathy is a condition which is accompanied by pain and results in joint dysfunction and reduced exercise tolerance. Indeed, this common sports-related condition is estimated to account for 30-50% of sporting injuries\(^1\). For example, it is known to affect up to 30% of runners, with the Achilles tendon being the most commonly affected (56.6%)\(^2\). Similarly, around 40% of athletes involved in racket sports...
The efficacy and safety of oral mucopolysaccharide, type I collagen and vitamin C treatment in tendinopathy patients

present tendinopathy of the lateral epicondyle tendon (tennis elbow) at some point in their career. Although the term tendinitis has historically been used, histological studies have shown that the affected tendon is essentially free from inflammation. In contrast, tendinopathy is characterized by a degeneration of the extracellular matrix, with a structural disorganization of the collagen fibers and neovascularization.

Traditional therapeutic strategies based on the use of anti-inflammatories have been found to be ineffective at correcting the evolution of this condition. Although numerous therapeutic alternatives for treating tendon disorders are known, the majority are considered to lack a scientific basis, the main exception to this being eccentric exercises, which are particularly useful for treating chronic, non-insertional Achilles tendinopathy. In light of the above, the present study evaluates the therapeutic efficacy of a nutritional supplement (Tendoactive™) containing mucopolysaccharides, type I collagen and vitamin C. In vitro studies in tendinopathy models have shown the potential of this supplement for correcting structural alterations in the extracellular matrix of the tendon.

Materials and methods

A multicenter, open-label, non-comparative, prospective, exploratory phase IV study was performed to study the efficacy of Tendoactive™ (Bioiberica S.A., Palaolls, Spain) for treating patients with clinically and ultrasound-diagnosed diagnosis tendinopathy. The study was performed in accordance with national and international guidelines concerning research in human subjects, such as the Declaration of Helsinki. All participants provided written informed consent for their participation and the protocol was approved by the ethics committee from the Consell Català de l’Esport (Generalitat de Catalunya).

A total of 98 patients of both sexes aged 18 years or older were included (32 with Achilles tendinopathy, 32 with patellar tendinopathy and 34 with lateral epicondyle tendinopathy, or tennis elbow). The diagnosis of tendinopathy was based on a clinical examination, with swelling of the tendon that was painful upon palpation, and confirmed by ultrasound as local swelling of the tendon, an irregular structure with hypoechoic regions and irregular orientation of the fibers. Patients with clinically suspected systemic disease (spondyloarthritis, gout, hyperlipidemia, rheumatoid arthritis, sarcoidosis) or a neurological disorder were excluded. Pregnant women were also excluded. As this was a pilot exploratory study, the sample size was determined using publications concerning similar studies as reference. All patients included in the study took 3 capsules of Tendoactive™ (435 mg mucopolysaccharides, 75 mg type I collagen and 60 mg vitamin C) per day for 90 consecutive days. Patients were followed-up monthly, with visits at days 30, 60 and 90 after commencement of treatment. The day prior to commencement of treatment (day 0) was established as the baseline visit.

Joint function was assessed at each visit using the validated Victorian Institute of Sport Assessment questionnaire specific for the Achilles (VISA-A) or patellar tendon (VISA-P). The validated Patient-rated Tennis Elbow Evaluation (PRTEE) questionnaire was used to assess elbow function. Pain intensity was determined at rest and when active using a 10-centimetre visual analogue scale (VAS). At each visit the tendon was characterized by ultrasound, including measuring the bilateral cross-sectional thickness of the two Achilles tendons at the point of maximum swelling, and the type of tendinopathy, degree of effacement of the paratenon, degree of heteroechogenicity, hypoechogenicity, neovascularization and the presence of isolated intratendinous ruptures was determined.

Analgesic consumption and the appearance of any adverse effect were recorded throughout the experimental period. Patient satisfaction with the treatment was assessed at each visit using a subjective assessment question.

All data obtained were subjected to a descriptive statistical analysis. A repeated measures analysis, with time as an inter-individual factor, was performed using the TOEP-type MIXED model in the Statistical Analysis System software package (version 6.11; SAS Institute, Cary, NC, USA) to evaluate the efficacy throughout the experimental period. The LS-MEANS test was used to compare means. Categorical variables were analyzed using the Wilcoxon test. Statistical significance was established at $\alpha = .05$.

Results

A total of 98 patients complied with the inclusion criteria and agreed to participate in the study. These patients were recruited from the 17 participating medical centers between September 2012 and January 2013. As 28 patients did not complete the entire follow-up period, a total of 70 patients complied with the established protocol. The mean age of the participants was 49.2 ± 3.64 years for the Achilles tendinopathy group (AC group), 47.7 ± 1.69 years for the patellar tendinopathy group (PA group) and 39.0 ± 2.44 years for the lateral epicondyle tendinopathy group (LE group). Similarly, the BMI was 24.1 ± .73, 25.6 ± .75 and 23.1 ± .65 kg/m² for the AC, PA and LE groups, respectively.

A significant reduction in the pain experienced at rest (Figure 1) and when active (Figure 2) was observed for all three groups. This reduction was progressive throughout the study, and was significant at the first control visit performed on day 30 of treatment ($P < .01$). At the end of the study (day 90), the intensity of the pain at rest had decreased by 80% for the AC group, 71% for the PA group and 91% for the LE group with respect to baseline pain ($P < .001$), whereas pain when moving was reduced by 82% for the AC group, 73% for the PA group and 81% for the LE group ($P < .001$).

The functional questionnaires showed a linear improvement throughout the study (Figure 3). In agreement with the reduction in pain intensity, the functional improvement for all groups was significant from the first visit ($P < .001$). With respect to the baseline situation, the improvement recorded at the end of the study was 38%, 46% and 77% for the AC, PA and LE groups, respectively ($P < .001$).
A significant reduction in the thickness of the affected tendon was observed for all three patient groups (Figure 4). This reduction was 12% for the AC group, 10% for the PA group and 20% for the LE group ($P < .05$). The reduction for the AC and PA groups occurred between the baseline visit and second follow-up visit (day 60) and thereafter remained constant until the end of the study, whereas the reduction for the LE group was progressive from the onset of the study. Other ultrasound parameters also showed a structural improvement in the affected tendon for all patient groups (Table 1). The decrease in hypoechoogenicity was significant for the AC and LE groups, and tended to significance for the PA group, whereas the degree of neovascularization only decreased in patients with tennis elbow. The degree of heteroechoogenicity and effacement of the paratenon improved for the AC and LE groups, and to a lesser extent for the PA group, in which only a numerical improvement was detected.

Figure 1  Evolution of pain intensity at rest (VAS) with time.
* $P < .05$ with respect to the baseline visit.

Figure 2  Evolution of pain intensity when active (VAS) with time.
* $P < .05$ with respect to the baseline visit.

Figure 3  Evolution of the joint function scales VISA-A, VISA-P and PRTEE in patients with tendinopathy of the Achilles tendon, patellar tendon or lateral epicondylar tendon with time.
* $P < .05$ with respect to the baseline visit.

Figure 4  Evolution of the thickness of the affected tendon with time.
* $P < .05$ with respect to the baseline visit.
NSAID consumption decreased significantly during the study. Thus, for the AC group, the percentage of patients who had taken at least one dose of NSAID 30 days prior to the baseline visit was 28%, whereas this percentage decreased to 5% in the 30 days prior to the final visit (P < .05). The reduction was also significant for patients in the PA group (from 43% to 14%; P < .05), but was only numerical for the LE group (from 29% to 15%; P > .05).

The percentage of patients who evaluated the treatment received positively or very positively in the subjective acceptance questionnaire was 95% for the AC group, 90% for the PA group and 85% for the LE group. None of the patients evaluated the treatment negatively. As far as safety is concerned, no adverse effects were reported during the study.

**Discussion**

The aim of this study was to evaluate the efficacy and safety of a nutritional supplement containing mucopolysaccharides, type i collagen and vitamin C (Tendoactive™) on the clinical and structural evolution of tendinopathies. To this end, an open-label multicenter study was designed in order to study a relevant population of patients. The results obtained showed a significant improvement in the three types of tendinopathy included in this study. It should be noted that the three tendons studied (Achilles, patellar and lateral epicondylar) have distinctive characteristics, such as the paratenon or type of blood supply, thus meaning that they can be considered to represent anatomical variations of the various tendons present in the body. In light of this, the results obtained in this study could be applicable to the majority of tendons. Validated functional questionnaires (VISA-A, VISA-P, PRTEE) and a visual analog pain scale (VAS) were used to evaluate the improvements observed.

The results obtained are consistent with an initial observational-type pilot study in which treatment with Tendoactive™ produced a 69% pain reduction in patients with Achilles tendinopathy, 83% in patients with tennis elbow and 75% in patients with supraspinous tendinopathy. The pain reduction obtained in the present study after treating Achilles patients for 12 weeks (80%) is equivalent to that described using other therapeutic strategies, such as eccentric exercises. In other studies, pain reductions of between 60% and 84% have been obtained in those tendons that respond to treatment after 12 weeks.

In the case of patellar tendinopathy, reductions of 31% in pain intensity and functional improvements of 67% in VISA-P have been obtained at 12 weeks after an intervention with PRP and a physical therapy programme. Treatment Tendoactive™ resulted in a pain reduction of 71% and an improvement in the VISA-P test of 46%, although these values may be affected by the fact that all ultrasound-confirmed patellar tendinopathies were included in this study, whereas only patients with degenerative tendinopathy and clinical symptoms lasting for more than 12 months were included in the PRP and physical therapy study.

In studies involving lateral epicondylalgia patients, pain reductions of 81% have been reported when using an eccentric exercise protocol, whereas pain reduction in the present study was 91%.

---

**Table 1 Ultrasound characterization of the affected tendon before and after treatment**

<table>
<thead>
<tr>
<th>Degree of severity</th>
<th>Baseline (d0) (%)</th>
<th>End (d90) (%)</th>
<th>P value</th>
<th>Baseline (d0) (%)</th>
<th>End (d90) (%)</th>
<th>P value</th>
<th>Baseline (d0) (%)</th>
<th>End (d90) (%)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AC Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>33</td>
<td>94</td>
<td>&lt; .0001</td>
<td>28</td>
<td>71</td>
<td>.0012</td>
<td>21</td>
<td>75</td>
<td>.0015</td>
</tr>
<tr>
<td>1</td>
<td>39</td>
<td>6</td>
<td></td>
<td>33</td>
<td>29</td>
<td></td>
<td>37</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>22</td>
<td>0</td>
<td></td>
<td>33</td>
<td>0</td>
<td></td>
<td>42</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>0</td>
<td></td>
<td>6</td>
<td>0</td>
<td></td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>PA Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>42</td>
<td>64</td>
<td>NS</td>
<td>15</td>
<td>38</td>
<td>NS</td>
<td>28</td>
<td>60</td>
<td>.0737</td>
</tr>
<tr>
<td>1</td>
<td>42</td>
<td>29</td>
<td></td>
<td>55</td>
<td>46</td>
<td></td>
<td>17</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>16</td>
<td>0</td>
<td></td>
<td>10</td>
<td>0</td>
<td></td>
<td>39</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>7</td>
<td></td>
<td>20</td>
<td>15</td>
<td></td>
<td>17</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>LE Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>40</td>
<td>79</td>
<td>.0231</td>
<td>17</td>
<td>53</td>
<td>.0035</td>
<td>15</td>
<td>63</td>
<td>&lt; .0001</td>
</tr>
<tr>
<td>1</td>
<td>48</td>
<td>21</td>
<td></td>
<td>46</td>
<td>42</td>
<td></td>
<td>15</td>
<td>26</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>8</td>
<td>0</td>
<td></td>
<td>25</td>
<td>0</td>
<td></td>
<td>31</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>0</td>
<td></td>
<td>13</td>
<td>5</td>
<td></td>
<td>38</td>
<td>5</td>
<td></td>
</tr>
</tbody>
</table>

NS: not significant.

a Percentage distribution of the patients on the severity scales for each of the ultrasound evaluation parameters.
b P value for the comparison of the percentage distribution of patients before and after treatment.
Although they have been associated with some degree of subjectivity, pain scales and functional questionnaires are valid and useful tools for clinically assessing tendinopathies. In contrast, ultrasound characterization parameters are purely objective and allow the structural evolution of the tendon to be analyzed. It is significant that the clinical improvements observed in the three types of tendinopathy studied are associated with structural improvements such as a reduced thickness of the affected tendon, or a lesser degree of neovascularization in the LE group. Similar associations have been described in other studies. This, in 2010, Humphrey et al. published a study in which a clinical improvement of 82% in the VISA-A scale was associated with a 13% reduction in tendon thickness and reduced neovascularization in patients with non-insertional Achilles tendinopathy treated with high-volume ultrasound-guided injections.

Although the mechanism by which Tendoactive™ exerts its effect is not fully understood, in vitro studies have shown that it helps to restore the equilibrium in the extracellular matrix of the tendon, stimulates type I collagen synthesis and counteracts the catabolic mechanisms in tenocytes undergoing a degenerative process, thereby increasing their proliferation and cell activity.

This study provides evidence regarding the efficacy of Tendoactive™ for the treatment of tendinopathies. The strong points of this study are the use of a sufficient number of patients and the ultrasound-based follow-up of the affected tendons. The main weakness of this study is the lack of a control group that can be used to compare the evolution of the patients. However, both the clinical and ultrasound findings are significant and consistent, and suggest the need for a controlled, randomized study.

Conflict of interests

Authors declare that they don’t have any conflict of interests.

References